Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Persistence of warfarin therapy for residents in long-term care who have atrial fibrillation.

Patel AA, Reardon G, Nelson WW, Philpot T, Neidecker MV.

Clin Ther. 2013 Nov;35(11):1794-804. doi: 10.1016/j.clinthera.2013.09.010. Epub 2013 Oct 15.

PMID:
24139051
2.

Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation.

Spivey CA, Qiao Y, Liu X, Mardekian J, Parker RB, Phatak H, Claflin AB, Kachroo S, Abdulsattar Y, Chakrabarti A, Wang J.

J Manag Care Spec Pharm. 2015 Jul;21(7):596-606.

3.

Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting.

McCormick D, Gurwitz JH, Goldberg RJ, Becker R, Tate JP, Elwell A, Radford MJ.

Arch Intern Med. 2001 Nov 12;161(20):2458-63.

PMID:
11700158
4.

Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.

Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):567-74. doi: 10.1161/CIRCOUTCOMES.113.000192. Epub 2013 Aug 6. Erratum in: Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e59.

5.

Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home.

Reardon G, Pandya N, Nutescu EA, Lamori J, Damaraju CV, Schein J, Bookhart BK.

Am J Geriatr Pharmacother. 2012 Dec;10(6):361-72. doi: 10.1016/j.amjopharm.2012.11.003.

PMID:
23217529
6.
7.

Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?

Gallagher AM, Rietbrock S, Plumb J, van Staa TP.

J Thromb Haemost. 2008 Sep;6(9):1500-6. doi: 10.1111/j.1538-7836.2008.03059.x. Epub 2008 Jun 28.

8.

Atrial fibrillation and stroke prevention with warfarin in the long-term care setting.

Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J.

Arch Intern Med. 1997 May 12;157(9):978-84.

PMID:
9140268
9.

Warfarin use in nursing home residents: results from the 2004 national nursing home survey.

Ghaswalla PK, Harpe SE, Slattum PW.

Am J Geriatr Pharmacother. 2012 Feb;10(1):25-36.e2. doi: 10.1016/j.amjopharm.2011.12.001. Epub 2012 Jan 9.

PMID:
22226690
10.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
11.

Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation.

Song X, Sander SD, Varker H, Amin A.

Am J Cardiovasc Drugs. 2012 Aug 1;12(4):245-53. doi: 10.2165/11632540-000000000-00000.

PMID:
22775446
12.

Stroke associated with discontinuation of warfarin therapy for atrial fibrillation.

Spivey CA, Liu X, Qiao Y, Mardekian J, Parker RB, Phatak H, Masseria C, Kachroo S, Abdulsattar Y, Wang J.

Curr Med Res Opin. 2015 Nov;31(11):2021-9. doi: 10.1185/03007995.2015.1082995. Epub 2015 Sep 21.

PMID:
26390258
13.

Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.

Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC.

Am J Kidney Dis. 2015 Oct;66(4):677-88. doi: 10.1053/j.ajkd.2015.05.019. Epub 2015 Jul 7.

14.

Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study.

Tsivgoulis G, Spengos K, Zakopoulos N, Manios E, Peppes V, Vemmos K.

Age Ageing. 2005 Jan;34(1):35-40.

PMID:
15591481
15.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

16.

Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.

Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK.

Clin J Am Soc Nephrol. 2011 Nov;6(11):2662-8. doi: 10.2215/CJN.04550511. Epub 2011 Sep 29.

17.

Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation.

Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV, Schein JR.

Curr Med Res Opin. 2014 Dec;30(12):2461-9. doi: 10.1185/03007995.2014.933577. Epub 2014 Jun 25.

PMID:
24926732
18.

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study.

Turakhia MP, Hoang DD, Xu X, Frayne S, Schmitt S, Yang F, Phibbs CS, Than CT, Wang PJ, Heidenreich PA.

Am Heart J. 2013 Jan;165(1):93-101.e1. doi: 10.1016/j.ahj.2012.10.010. Epub 2012 Nov 20.

PMID:
23237139
19.

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S.

Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.

20.

One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.

Chen SY, Wu N, Gulseth M, LaMori J, Bookhart BK, Boulanger L, Fields L, Schein J.

J Manag Care Pharm. 2013 May;19(4):291-301.

Supplemental Content

Support Center